NCT02477514View on ClinicalTrials.gov

A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Skin Diseases, Bacterial
Interventions
DRUG

midazolam

2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14

DRUG

rosuvastatin

10 mg tablet administered as a single oral dose on Days 3 and 16

DRUG

tedizolid phosphate

200 mg oral tablet administered once daily on Days 5-17

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02477514 - A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004) | Biotech Hunter | Biotech Hunter